


**Rheumatology Association of Nevada  
4th Annual Meeting  
Saturday, April 27, 2019**

Planet Hollywood Resort and Casino  
Las Vegas, Nevada

**PROGRAM BOOK**

---



# WELCOME

Dear Fellow Rheumatologists,

As the current President of the Rheumatology Association of Nevada, I welcome you to our 4th Annual Meeting, April 27, 2019, at the Planet Hollywood Resort and Casino in Las Vegas. I would like to acknowledge the efforts of our Officers and Board Members. I want to especially mention my predecessor, Ewa Olech, MD and her outstanding leadership as RAN's Inaugural President, as well as WJ Weiser & Associates, Inc. and Donna Rostamian, MBA, Executive Director of RAN for their assistance in organizing our 4th Annual Meeting. We also know that this meeting could not happen without our many generous sponsors.

We had a great meeting last year on April 28, 2018, in Lake Tahoe, Nevada. For those of you unable to attend, we had a variety of front-line presentations. Cutting edge topics included reviews of emerging novel therapies in rheumatoid arthritis, biologics use and biosimilars, and updates on PSA, ANCA vasculitis, pediatric auto-inflammatory conditions, and suicide prevention.

This year our keynote speaker is Leonard Calabrese, DO, of the Cleveland Clinic Foundation. He will give two presentations on rheumatoid complications of cancer immunotherapy and viral infections and rheumatic disease. We are grateful to welcome Michelle Petri, MD, MPH of Johns Hopkins University School of Medicine, who will give a review of systemic lupus erythematosus. Vibeke Strand, MD, MACR, FACP will present a timely update of JAK/STATs inhibitors and their use in rheumatoid arthritis care. We will also receive a CSRO advocacy update from Madelaine A. Feldman, MD, FACP of The Rheumatology Group. She will present a discussion about pharmacy benefit managers and their impact on rheumatologists and our patient care efforts. We will also have an industry sponsored symposium lunch and throughout the day will have networking opportunities with each other and industry.

We are very excited about this year's presenters and program and are pleased to be offering up to 6.00 hours of CME for attendance. We thank you for adding the RAN 4th Annual Meeting to your busy schedules. Welcome to Las Vegas!

Sincerely,

G. Timothy Kelly, MD, FACR  
RAN President

## 2018 - 2019 BOARD OF DIRECTORS

### OFFICERS

#### **President**

G. Timothy Kelly, MD, FACR

#### **Vice President**

Susan Knowles, MD

#### **Secretary**

Carolyn F. Dennehey, MD

#### **Treasurer**

Christianne Yung, MD

#### **Past President**

Ewa Olech, MD

### BOARD MEMBERS

Neil A. Braunstein, MD

Elise K. Call, PA-C

Ruth Chan, DO

William Kim, MD

Robert Lowe, MD, PhD

### 2019 PROGRAM COMMITTEE

G. Timothy Kelly, MD, FACR,  
*(Program Chair)*

Carolyn F. Dennehey, MD

Susan Knowles, MD

Ewa Olech, MD

Christianne Yung, MD

### HEADQUARTER OFFICE

WJ Weiser & Associates, Inc.

1100 E. Woodfield Road, Suite 350

Schaumburg IL 60173

(847) 517-7225 Fax: (847) 517-7229

#### **Executive Director**

Donna Rostamian, MBA

#### **Associate Director**

Thomas Heidrich

# TABLE OF CONTENTS



Welcome Message .....	Inside Front Cover
2018 - 2019 Board of Directors.....	Inside Front Cover
CME Information.....	2
Scientific Program.....	3
Faculty Disclosure Report.....	4
Biosketches .....	6
General Meeting Information .....	7
Industry Symposium .....	8
Industry Support .....	9
Exhibit Hall Floor Plan .....	10
Notes .....	12

## DISCLAIMER STATEMENT

Statements, opinions, and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of RAN, nor does RAN provide any guarantee as to their accuracy or reliability.

## COPYRIGHT NOTICE

Individuals may print out single copies of slides contained in this publication for personal, non-commercial use without obtaining permission from the author or RAN. Permission from both RAN and the author must be obtained when making multiple copies for personal or educational use, for reproduction for advertising or promotional purposes, for creating new collective works, for resale or for all other uses.

## FILMING/PHOTOGRAPHY STATEMENT

No attendee/visitor at the RAN 4th Annual Meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the RAN Executive Director. This policy applies to all RAN members, non-members, guests, and exhibitors, as well as members of the print, online, or broadcast media.

# CME INFORMATION

## **Educational Needs**

The Rheumatology landscape is an evolving one. The interest in and application of the use of biologic medications has revolutionized care in rheumatologic illness and care. Other disease classes, oncologic, allergic, dermatologic and others now have biologic treatment options. More than half of new medication applications to the FDA are biologic medications.

With the use of biologic agents comes the phenomenon of immunogenicity. That is body's production of an immune response as a result of the biologic's presence. Issues can include a subsequent loss of benefit of the medication or the development of an additional autoimmune disorder. One new issue recently noted is the observed immunogenicity of the new biologic medications used to treat small cell lung cancer. Various types of autoimmune diseases are developing in individuals receiving this class of medications.

Additionally, a new class of medications has arrived on the scene, the so-called small molecules. These agents work intracellularly to affect immunomodulation. These agents have found use in rheumatoid arthritis, the spectrum of psoriatic disease and other applications are being explored.

Systemic lupus erythematosus is perhaps the most well known of the rheumatologic autoimmune disorders. It is always helpful to review this complex spectrum of illness. Many agents have failed at clinical trials to show benefit for treatment. Newer considerations are however evolving.

Viral infections can cause various rheumatic manifestations. The production of immunogenicity is by virus proteins and leads to a wide spectrum of disorders and symptoms.

The system of patient medication procurement includes influence by industry pharmacy benefit managers. These positions have great impact on medication availability and cost. As rheumatologists, we need to be aware of how our patients' best interests can be protected.

## **Educational Objectives**

At the conclusion of the RAN 4th Annual Meeting, attendees will be able to:

1. Describe the history of immunotherapy.
2. Relate the Immunopathogenesis of checkpoint inhibitors to immune related adverse events (irAEs).
3. Diagnose and manage irAEs.
4. Explain the function of drug rebates in the health insurance system and the impact on costs for patients.
5. Describe the microbiology and epidemiology of common viral infections.
6. Relate the Immunopathogenesis of viral infections as etiologies, comorbidities and complications of targeted therapies.
7. Diagnose and manage viral infections.
8. Identify Lupus low disease activity state as a T2T as it reduces later organ damage.
9. Discuss prediction of cardiovascular events using the Lupus Cardiovascular risk equation.
10. Review successful phase 2 and 3 trials in SLE.
11. Describe the class of JAK/STAT inhibitors.
12. Identify what therapeutic indications have been approved in the US for Tofacitinib and Baricitinib.
13. Name 4 dermatologic indications in which JAKs have been studied.
14. Describe what gastrointestinal indications have been studied for JAK's.
15. Discuss factors that contribute to immunogenicity that are disease related, product related, patient related and treatment related.
16. Describe the potential consequences of immunogenicity.
17. Describe what can be done to prevent/mitigate immunogenicity.

**SAPS CME ACCREDITATION STATEMENT:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of the Southern Alliance for Physician Specialties CME and the Rheumatology Association of Nevada. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of **6.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for **AMA PRA Category 1 Credit™** from organizations accredited by the ACCME, please consult your professional licensing board.

## **General Disclaimer**

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Rheumatology Association of Nevada. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Rheumatology Association of Nevada disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

## **Special Assistance**

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517 - 7225 if you require special assistance to fully participate in the meeting.

# SCIENTIFIC PROGRAM

## RHEUMATOLOGY ASSOCIATION OF NEVADA 4TH ANNUAL MEETING

April 27, 2019

Planet Hollywood Las Vegas

All sessions will be located in **Melrose 4** unless otherwise noted.  
Speakers and times are subject to change.

### SATURDAY, APRIL 27, 2019

**7:30 a.m. - 4:30 p.m. Registration/Information Desk Hours**  
*Location: Melrose Foyer*

**7:30 a.m. - 8:30 a.m. Continental Breakfast in the Exhibit Hall**  
*Location: Melrose 1-3*

**7:30 a.m. - 1:30 p.m. Exhibit Hall Hours**  
*Location: Melrose 1-3*

#### GENERAL SESSION

**8:15 a.m. - 8:30 a.m. Welcome & Opening Remarks**  
President: G. Timothy Kelly, MD

**8:30 a.m. - 9:30 a.m. Rheumatic Complications of Cancer Immunotherapy: A New and Emerging Field in Rheumatology**  
Invited Speaker: Leonard Calabrese, DO  
*Cleveland Clinic Foundation*

**9:30 a.m. - 10:15 a.m. Viral Infections and Rheumatic Disease: Etiology, Co-Morbidities and Complications**  
Invited Speaker: Leonard Calabrese, DO  
*Cleveland Clinic Foundation*

**10:15 a.m. - 11:00 a.m. Break & Networking - Exhibit Hall**  
*Location: Melrose 1-3*

**11:00 a.m. - 12:00 p.m. Non-Renal Systemic Lupus Erythematosus Update**  
Michelle Petri, MD, MPH  
*Johns Hopkins University School of Medicine*

**12:00 p.m. - 1:00 p.m. Industry Satellite Lunch Symposia**  
*Location: Sunset 3 - 4*

**1:00 p.m. - 1:30 p.m. Dessert & Networking in Exhibit Hall**  
*Location: Melrose 1-3*

**1:30 p.m. - 2:15 p.m. CSRO Update: Pharmacy Benefit Managers**  
Madelaine A. Feldman, MD, FACR  
*The Rheumatology Group*

**2:15 p.m. - 3:15 p.m. Exploring the Role of JAK-Inhibitors Across the Spectrum of IMiDs**  
Vibeke Strand, MD, MACR, FACP  
*Loftis/Strand Consulting*

**3:15 p.m. - 4:00 p.m. Lessons Learned from Biologic Agents in Rheumatology - Immunogenicity**  
Vibeke Strand, MD, MACR, FACP  
*Loftis/Strand Consulting*

**4:00 p.m. - 4:15 p.m. Q & A Session**

**4:15 p.m. - 4:30 p.m. RAN Annual Business Meeting**

**4:30 p.m. - 4:45 p.m. Closing Remarks & Adjournment**  
President: G. Timothy Kelly, MD

#### Disclaimer Statement

Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of RAN nor does RAN provide any warranty as to their accuracy or reliability.

#### REGISTRATION/INFORMATION DESK HOURS

*Location: Melrose Foyer*

**Friday, April 26, 2019** 4:30 p.m. - 7:00 p.m.

**Saturday, April 27, 2019** 7:30 a.m. - 4:30 p.m.

#### EXHIBIT HALL HOURS

*Location: Melrose 1-3*

**Saturday, April 27, 2019** 7:30 a.m. - 1:30 p.m.

# DISCLOSURE REPORT

## FACULTY DISCLOSURE REPORT

Rheumatology Association of Nevada 4th Annual Meeting  
 April 27, 2019  
 Las Vegas, NV

In accordance with the ACCME Accreditation Criteria, the Southern Alliance for Physician Specialties (SAPS), as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a 'commercial interest' as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients". It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers "relevant" financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

PLANNING COMMITTEE / CME ORGANIZERS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
DENNEHEY, MD, Carolyn CME Organizer	Abbvie, Novartis	Consultant	Speakers Bureau
KELLY, MD, G. Timothy President, CME Organizer	AbbVie, Amgen, Lily, Novartis	Other Financial or Material Support	Speaker's Bureau
KNOWLES, MD, Susan CME Organizer	Lilly	Consultant	Consultant
OLECH, MD, Ewa CME Organizer	Amgen, Pfizer	Consultant	Consulting
	BMS	Grants/Research Support	Contracted Research
	Abbvie, Amgen, Merck, Pfizer	Other Financial or Material Support	Speaker's Bureau
YUNG, MD, Christianne CME Organizer	GlaxoSmithKline	Grants/Research Support	Contracted Research

SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
CALABRESE, DO, Leonard Speaker	AbbVie, BMS, Crescendo Bioscience, Genentech, Gilead Sciences, GSK, Horizon Pharma, Janssen, UCB	Consultant	Consulting
FELDMAN, MD, FACR, Madelaine Speaker	Lilly	Consultant	Advisory Board
KELLY, MD, G. Timothy President, CME Organizer	AbbVie, Amgen, Lily, Novartis	Other Financial or Material Support	Speaker's Bureau

# DISCLOSURE REPORT

SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
PETRI, MD, MPH, Michelle Speaker	GlaxoSmithKline	Grants/Research Support	Member of Pregnancy Registry DSMB
	EMD Serono	Consultant	Member DSMB
	Exagen	Grants/Research Support	Participant in Clinical Trial
	Axdev	Consultant	Faculty Board
	Amgen, Eli Lilly, Bristol Myer Squibb, Janssen, United Rheumatology	Consultant	Advisory Board
	Abbvie, Aleon Pharm, Astellas	Consultant	Advisory Board
	Blackrock Pharm, Glenmark Pharm, Kezar Life Sci, Momenta Pharm, Novartis, Principia Biopharma, Qiagen, UCB Phram	Consultant	Advisory Board
	IQVIA	Consultant	Member DSMB
	AstraZeneca	Grants/Research Support	PI on Clinical Trial
STRAND, MD, MACR, FACP, Vibeke Speaker	Syntex Research, Applied Immune Sciences, Xoma Corporation	Employee of a Commercial Interest Organization	Previously Employed
	OMERACT	Grants/Research Support	Founding Member of Executive Committee - Rheumatology Controlled Trials and Observational Studies
	AbbVie, Amgen, AstraZeneca, Bayer, BMS, Celltrion, Crescendo, EMDSerono, Genentech / Roche, GSK, Horizon, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, Selecta, UCB	Consultant	Advisory Board
	AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celltrion, Crescendo / Myriad Genetics, EMD Erono, Eupraxia, Flexion, Genentech / Roche, Glenmark, GSK, Inmedix, Janssen, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Samumed, Sandoz, Sanofi, Selecta, Servier, Setpoint, SKK, UCB	Consultant	Consultant
	American College of Rheumatology	Grants/Research Support	Clinical Trials Task Force

# BIOSKETCHES

## **Leonard Calabrese, DO**

Dr. Calabrese is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Vice Chair of the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is the director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic specializing in diseases of the immune system, in particular, immunodeficiency diseases including HIV. Dr. Calabrese has extensively published on the safety of biologic therapies for autoimmune diseases including the epidemiology of opportunistic and viral infections. Dr. Calabrese is also the Co-director of the Center for Vasculitis Care and Research and holds a joint appointment in the Department of Infectious Diseases. Dr. Calabrese has lectured nationally and internationally on the subjects of clinical immunology, rheumatology and virology and is the author of over 400 published peer reviewed articles, book chapters and reviews.

## **Madelaine A. Feldman, MD, FACR**

Dr. Feldman is in private practice in New Orleans and is the president of the Coalition of State Rheumatology Organizations, the founding member and past president of the Rheumatology Alliance of Louisiana, and served on the insurance subcommittee for the ACR. She is the Chair of the Alliance for Safe Biologic Medicines. She has served on the board of the Institute for Patient access and biologic working group for AfPA. A Clinical Assistant Professor of Medicine at Tulane University School of Medicine she has been named one of the Top Doctors in New Orleans for over 15 years. She was awarded the Distinguished Service Award in 2018 by the Tulane Medical Alumni association and named one of the 2017 top 50 women in New Orleans by New Orleans City Business.

## **G. Timothy Kelly, MD**

Dr. Kelly graduated with a BA in Psychology and a AS in Chemistry from Brigham Young University in Provo, Utah. He then went on to earn his MD from the University of Nevada in Reno, Nevada. Dr. Kelly then completed his Internship and Residency at the University Medical Center of Southern Nevada in Las Vegas followed by a Clinical, then Research Fellowship in Rheumatology at Loma Linda University Medical Center in Loma Linda, California. Dr. Kelly is currently a Clinical Professor at the University of Nevada School of Medicine and is involved with Innovative Health Research.

## **Michelle Petri, MD, MPH**

Dr. Petri is a Professor of Medicine in the Division of Rheumatology and Director of the Lupus Center at the Johns Hopkins University School of Medicine and Johns Hopkins Hospital in Baltimore, Maryland. She earned her medical degree from Harvard Medical School in Boston, Massachusetts, and completed her internship and residency in Internal medicine at Massachusetts General Hospital. Thereafter, Professor Petri completed her Postdoctoral Fellowship in Allergy, Immunology, and Rheumatology at the University of California, San Francisco. She subsequently earned her master's in Public Health and Epidemiology from Johns Hopkins University Bloomberg School of Public Health. Dr. Petri's research focuses on several aspects of systemic lupus erythematosus (SLE), including atherosclerosis, antiphospholipid syndrome (APS), lupus nephritis, and pregnancy. The Hopkins Lupus Cohort, started by Professor Petri in 1987, is a longitudinal study of the incidence and pathogenesis of thrombotic events and coronary artery disease in SLE. Its serum and plasma bank is a useful resource for other SLE-related research. The Hopkins Lupus Pregnancy Center, of which Professor Petri is a Co-Director, has a database of over 400 pregnant patients, providing information on lupus activity, antiphospholipid tests, and pregnancy outcomes. As part of the Systemic Lupus International Collaborating Clinics, Hopkins participates in studies of atherosclerosis, malignancy, and neuropsychiatric lupus. Professor Petri has served as study Chair or Principal Investigator for several of these studies on the SLE patient population.

## **Vibeke Strand, MD, MACR, FACP**

Dr. Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years - in subspecialty practice in San Francisco, as a clinical investigator and subsequently senior director of clinical research at 3 pharmaceutical/biotech companies. She has served as Adjunct Clinical Professor, Division of Immunology and Rheumatology at Stanford University since September 2000; Clinical Associate Professor to March 1993, and Assistant and Associate Clinical Professor at University of California San Francisco (1981-1993). Since 1991, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results and presentation of novel products for approval to FDA and EMA. She has assisted in preparation of briefing documents, analyses and data presentation for defense of NDA and BLA applications in RA, SLE, PsA, SpA, SSc, uveitis, OA, gout, FMS and the first monoclonal antibody biosimilar. She has been an invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents.



# SATELLITE SYMPOSIUM

INDUSTRY SPONSORED SYMPOSIUM EVENT

SATURDAY, APRIL 27, 2019

12:00 p.m. - 1:00 p.m.

---

**Industry Satellite Symposium Lunch\***

*Location: Sunset 3 - 4*

Sponsored by: Bristol-Myers Squibb

**“Investigating Changes in Serology and Clinical Outcomes in RA Following Treatment with ORENCIA (abatacept) Plus Methotrexate”**

Orrin M. Troum, MD

Santa Monica, CA

*\*Not CME Accredited*

**taltz**<sup>®</sup>  
(ixekizumab)  
injection  
80 mg/mL

**COME FOR  
THE DATA  
STAY FOR THE  
RESULTS**



**MEET TALTZ  
AT BOOTH LOCATION**

---

Learn about the Taltz Savings Card Program at [taltz.com/hcp](http://taltz.com/hcp)

---

If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company's Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

Taltz is a registered trademark of Eli Lilly and Company. PP-IX-US-1020 11/2016 ©2016, LILLY USA, LLC. ALL RIGHTS RESERVED. PRINTED IN USA ON POST-CONSUMER RECYCLED PAPER ♻️

# INDUSTRY SUPPORT

THANK YOU TO OUR 2019 PROMOTIONAL PARTNERS

GOLD LEVEL PARTNER



SILVER LEVEL PARTNERS



THANK YOU TO OUR 2019 CONTRIBUTORS

Bristol-Myers Squibb

Lilly

THANK YOU TO OUR 2019 EXHIBITORS

AbbVie

AbbVie Medical Affairs

Amgen, Inc.

Bristol-Myers Squibb

Celgene Corporation

Exagen Diagnostics, Inc.

Flexion Therapeutics

Genentech

Gilead Sciences

GlaxoSmithKline

Horizon Pharma, Inc.

Janssen Biotech, Inc.

Lilly

Mallinckrodt Pharmaceuticals

Medexus Pharma

Metro Medical

Novartis

Pfizer

Primus Pharmaceuticals, Inc.

Sanofi Genzyme Regeneron

UCB, Inc.



# WORKING TOGETHER FOR *Patients*<sup>™</sup>

At Bristol-Myers Squibb, we are  
working together for patients

Our mission is clear — we discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients. **It's what we do. It's why we do it.**

Bristol-Myers Squibb is proud to support the 2019 Rheumatology Association of Nevada Conference



**Bristol-Myers Squibb**

[bms.com](http://bms.com)

© 2019 Bristol-Myers Squibb Company.




## Pushing the boundaries of science

At UCB, everything we do starts with a simple question: **"How will this add value to the lives of people living with severe diseases?"**

We are driven every day to help tackle serious unmet medical needs affecting hundreds of thousands of patients around the globe who are living with severe neurological and immunological disorders.



# EXHIBIT HALL FLOOR PLAN



# EXHIBIT HALL FLOOR PLAN

Company Name	Booth #	Company Name	Booth #
AbbVie	<b>22</b>	Janssen Biotech, Inc.	<b>14</b>
AbbVie Medical Affairs	<b>10,11</b>	Lilly	<b>4,5</b>
Amgen, Inc.	<b>8</b>	Mallinckrodt Pharmaceuticals	<b>17</b>
Bristol-Myers Squibb	<b>1</b>	Medexus Pharma	<b>18</b>
Celgene Corporation	<b>16</b>	Metro Medical	<b>21</b>
Exagen Diagnostics, Inc.	<b>19</b>	Novartis	<b>2,3</b>
Flexion Therapeutics	<b>7</b>	Pfizer	<b>23</b>
Genentech	<b>12,13</b>	Primus Pharmaceuticals, Inc.	<b>9</b>
Gilead Sciences, Inc.	<b>15</b>	Sanofi Genzyme Regeneron	<b>25</b>
GlaxoSmithKline	<b>20</b>	UCB, Inc.	<b>24</b>
Horizon Pharma, Inc.	<b>6</b>		

**XELJANZ<sup>®</sup> XR**   
[tofacitinib]  
extended release • 11 mg tablets

taltz®  
(ixekizumab)  
injection  
80 mg/mL



# COME FOR THE DATA STAY FOR THE RESULTS

MEET TALTZ  
AT BOOTH LOCATION

---

Learn about the Taltz Savings Card  
Program at [taltz.com/hcp](http://taltz.com/hcp)

---

If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company's Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

**SANOFI GENZYME**



**REGENERON**

Sanofi Genzyme and Regeneron are committed to providing resources to better understand the pathogenesis of rheumatoid arthritis and to research the unmet needs of patients with this disease.



**Visit our booth**



## **Rheumatology Association of Nevada**

Two Woodfield Lake

1100 E. Woodfield Road, Suite 350 | Schaumburg, IL 60173

Phone: (847) 517-7225 | Email: [info@rheumatologynevada.org](mailto:info@rheumatologynevada.org)